IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.32%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$359M
AUM Growth
+$359M
(+3.2%)
Cap. Flow
-$3.33M
Cap. Flow
% of AUM
-0.93%
Top 10 Holdings %
Top 10 Hldgs %
38.59%
Holding
92
New
21
Increased
23
Reduced
17
Closed
21
Top Buys
| 1 |
McKesson
MCK
|
$13.7M |
| 2 |
Centene
CNC
|
$10.3M |
| 3 |
Abbott
ABT
|
$9.85M |
| 4 |
Biogen
BIIB
|
$8.4M |
| 5 |
AMED
Amedisys
AMED
|
$8.09M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$17.9M |
| 2 |
Medtronic
MDT
|
$10M |
| 3 |
Hologic
HOLX
|
$8.86M |
| 4 |
Zimmer Biomet
ZBH
|
$8.78M |
| 5 |
Acadia Healthcare
ACHC
|
$8.19M |
Sector Composition
| 1 | Healthcare | 97.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Centene
CNC
$14.3B
| $18.5M | 5.13% | 225,000 +125,000 | +125% | +$10.3M |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $17.4M | 4.81% | 409,000 +90,000 | +28% | +$3.83M |
|
3
Cytokinetics
CYTK
$4.23B
| $14.8M | 4.1% | 325,000 | – | – |
|
4
Revvity
RVTY
$10.5B
| $14.1M | 3.89% | 70,000 +20,000 | +40% | +$4.02M |
|
|
5
McKesson
MCK
$85.4B
| $13.7M | 3.78% | +55,000 | New | +$13.7M |
|
6
Envista
NVST
$3.52B
| $13.5M | 3.74% | 300,000 +70,000 | +30% | +$3.15M |
|
7
Globus Medical
GMED
$8.27B
| $13M | 3.6% | 180,000 +30,000 | +20% | +$2.17M |
|
8
Pfizer
PFE
$141B
| $11.8M | 3.27% | 200,000 -50,000 | -20% | -$2.95M |
|
9
Elevance Health
ELV
$71.8B
| $11.6M | 3.21% | 25,000 | – | – |
|
10
Zentalis Pharmaceuticals
ZNTL
$122M
| $10.1M | 2.79% | 120,000 +30,000 | +33% | +$2.52M |
|
|
11
Abbott
ABT
$231B
| $9.85M | 2.73% | +70,000 | New | +$9.85M |
|
12
CVS Health
CVS
$92.8B
| $8.77M | 2.43% | 85,000 -65,000 | -43% | -$6.71M |
|
|
13
Biogen
BIIB
$19.4B
| $8.4M | 2.32% | +35,000 | New | +$8.4M |
|
|
AMED
14
DELISTED
Amedisys
AMED
| $8.09M | 2.24% | +50,000 | New | +$8.09M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $8.03M | 2.22% | 75,000 -23,000 | -23% | -$2.46M |
|
16
Fate Therapeutics
FATE
$120M
| $7.61M | 2.1% | 130,000 +35,000 | +37% | +$2.05M |
|
|
17
Acadia Healthcare
ACHC
$2.12B
| $7.28M | 2.02% | 120,000 -135,000 | -53% | -$8.19M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.28M | 2.02% | 200,000 -100,000 | -33% | -$3.64M |
|
19
Relay Therapeutics
RLAY
$619M
| $6.91M | 1.91% | 225,000 +85,000 | +61% | +$2.61M |
|
20
Heron Therapeutics
HRTX
$207M
| $6.85M | 1.89% | 750,000 +340,000 | +83% | +$3.1M |
|
21
AbbVie
ABBV
$372B
| $6.77M | 1.87% | 50,000 +15,000 | +43% | +$2.03M |
|
22
Tenet Healthcare
THC
$16.3B
| $6.54M | 1.81% | +80,000 | New | +$6.54M |
|
23
Labcorp
LH
$23.1B
| $6.28M | 1.74% | +20,000 | New | +$6.28M |
|
24
Intellia Therapeutics
NTLA
$1.22B
| $5.91M | 1.64% | 50,000 | – | – |
|
25
Edwards Lifesciences
EW
$47.8B
| $5.83M | 1.61% | 45,000 +10,000 | +29% | +$1.3M |
|